Kyowa Kirin's new CVC invests in Cellarity
Japanese biotech Kyowa Kirin (TYO:4151) today announced it has launched its corporate venture capital (CVC) fund and invested in its first biotech start-up.
In its 2021-2025 Medium Term Business Plan, Kyowa Kirin has committed to “provide pharmaceuticals for unmet medical needs” as one of its strategic pillars to realize the “successful creation and delivery of life-changing value,” which is stated in Kyowa Kirin’s vision.
As one of the efforts supporting that strategic pillar, Kyowa Kirin has invested in venture capital (VC) funds and focused internal resources to ensure greater access to cutting-edge biotechnologies. Kyowa Kirin initiated its internal CVC function as a way of increasing rapid access to the latest biotechnologies from which the future of drug discovery will emerge.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze